The Technical Analyst
Intra-Cellular Therapies [ITCI]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Intra-Cellular Therapies Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.57% $73.26
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7 092.10 mill |
| EPS: | -1.460 |
| P/E: | -50.18 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 96.81 mill |
| Avg Daily Volume: | 0.957 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -50.18 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.05x |
| Company: PE -50.18 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 70.99 - 75.54 ( +/- 3.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-24 | Mates Sharon | Buy | 11 382 | Common Stock |
| 2024-04-24 | Mates Sharon | Buy | 8 638 | Common Stock |
| 2024-04-24 | Mates Sharon | Sell | 11 382 | Stock Option (right to buy) |
| 2024-04-24 | Mates Sharon | Sell | 8 638 | Stock Option (right to buy) |
| 2024-03-31 | Van Nostrand Robert L | Buy | 79 | Common Stock |
| INSIDER POWER |
|---|
| 1.82 |
| Last 100 transactions |
| Buy: 523 032 | Sell: 503 157 |
Forecast:
16:00 - $73.25
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $73.25
Forecast 2: 16:00 - $73.25
Forecast 3: 16:00 - $73.25
SCORE
9.00
Buy
9.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $73.26 (1.57% ) |
| Volume | 0.567 mill |
| Avg. Vol. | 0.957 mill |
| % of Avg. Vol | 59.25 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ITCI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $71.42 | N/A | Active |
|---|
ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Latest Press Releases
2024-04-24 16:01:00 - Press Release
Intra-cellular Therapies Announces Closing Of $575 Million Public Offering Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
New york, april 24, 2024 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci) (“intra-cellular therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced that it has completed the sale of an additional 1,027,397 shares of its common stock at a public offering price of $73.00 per share on april 24, 2024, pursuant to the full exercise of the option granted by intra-cellular therapies to the underwriters in connection with its previously announced public offering of 6,849,316 shares of common stock, which closed on april 22, 2024.
2024-04-17 20:46:00 - Press Release
Intra-cellular Therapies Prices Public Offering Of Common Stock
New york, april 17, 2024 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci) (“intra-cellular therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share. all of the shares in the offering will be sold by intra-cellular therapies, with gross proceeds to intra-cellular therapies expected to be $500.0 million before deducting underwriting discounts and commissions and offering expenses. intra-cellular therapies has granted the underwriters a 30-day option to purchase up to an additional 1,027,397 shares on the same terms and conditions...
2024-04-16 16:06:00 - Press Release
Intra-cellular Therapies Announces Proposed Public Offering Of Common Stock
New york, april 16, 2024 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci) (“intra-cellular therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock. in connection with the offering, intra-cellular therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. all of the shares in the offering will be sold by intra-cellular therapies.
2024-04-16 07:00:00 - Press Release
Intra-cellular Therapies Announces Positive Phase 3 Topline Results From Study 501 Evaluating Lumateperone As Adjunctive Therapy In Patients With Major Depressive Disorder
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
2024-03-19 08:30:00 - Press Release
Intra-cellular Therapies Announces Executive Appointments And Leadership Changes
New york, march 19, 2024 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced the promotion of michael halstead, j.d. to the position of president. mr. halstead is currently serving as executive vice president and general counsel. in this newly created leadership role, mr. halstead will oversee several functions within the company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation. he will continue to report to dr. sharon mates, chairman and chief executive officer.
Latest News
2024-04-24 11:36:46 - InvestorPlace
3 Biotech Stocks With Skyrocketing Potential: April 2024
Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.
2024-04-17 10:26:03 - Zacks Investment Research
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
2024-04-17 08:41:04 - Zacks Investment Research
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
2024-02-27 08:00:00 - GlobeNewsWire
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA.
2024-02-23 09:46:11 - Zacks Investment Research
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
2024-02-21 22:08:19 - InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not that risky of an industry, the biotech space can often be speculative.
2024-02-21 10:16:14 - Zacks Investment Research
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
2024-02-10 22:51:46 - Seeking Alpha
Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven significant revenue growth. Intra-Cellular is running Phase 3 studies to expand Caplyta's label into major depressive disorder, presenting a potential future growth opportunity.
2024-01-02 08:00:00 - GlobeNewsWire
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.
2023-12-29 14:12:19 - Seeking Alpha
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have been some winners in the biotech sector - I have been fortunate to share a few successful tips with Seeking Alpha readers.